Skip to main content
. 2021 Oct 12;20(1):133–143. doi: 10.1007/s40258-021-00677-x

Fig. 1.

Fig. 1

Comparison of clinical and economic impact of DAA treatment according to different treatment policies. a Disease complications avoided and cost-savings (post-screening) over 20 years and BPT. b Disease complications avoided and cost-savings (2015–2019) over 20 years and BPT. DAA direct-acting antiviral, BPT break-even point in time